BVMed proposes wound care law amendments:
This article was originally published in Clinica
Even though modern wound care products are a proven means of saving costs in the long run, they are often rejected simply because of the initial price per item, says Joachim Schmitt, director of the German medical device industry association (BVMed). Speaking at a press conference of the German association for wound care, he said that traditional wound care products lead to longer healing times for patients, which in turn lead to higher costs for the health insurers. Among the proposals put forward by Mr Schmitt to promote the use of innovative products were the removal or easing of budgeting applied to procedures for the treatment of chronic wounds, and the inclusion of chronic wound care products in a special category for reimbursement.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.